PMID- 28083972
OWN - NLM
STAT- MEDLINE
DCOM- 20180403
LR  - 20210504
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 19
IP  - 6
DP  - 2017 Jun
TI  - Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in 
      patients with type 2 diabetes mellitus.
PG  - 897-900
LID - 10.1111/dom.12876 [doi]
AB  - The incidence of renal-related adverse events (AEs) with canagliflozin in 
      patients with type 2 diabetes mellitus from a pooled population of patients in 7 
      active- and placebo-controlled trials (N = 5598) and in a 104-week study vs 
      glimepiride (N = 1450) was low and similar in canagliflozin and non-canagliflozin 
      groups. In the study vs glimepiride, canagliflozin was associated with an initial 
      acute decrease in estimated glomerular filtration rate (eGFR) that attenuated 
      over time, while eGFR declined progressively over 104 weeks with glimepiride. The 
      incidence of renal-related AEs with canagliflozin was generally stable over time, 
      while the incidence with glimepiride increased over 104 weeks. In the present 
      analysis, based on postmarketing reports from the US Food and Drug Administration 
      Adverse Event Reporting System, a potential signal was identified for acute 
      kidney injury with all approved sodium glucose co-transporter 2 (SGLT2) 
      inhibitors (ie, canagliflozin, dapagliflozin and empagliflozin). The early onset 
      of acute kidney injury events with SGLT2 inhibitors in postmarketing reports 
      probably reflects the acute changes in eGFR attibutable to the known renal 
      haemodynamic effects of SGLT2 inhibition.
CI  - (c) 2017 Janssen Research & Development. Diabetes, Obesity and Metabolism published 
      by John Wiley & Sons Ltd.
FAU - Desai, Mehul
AU  - Desai M
AUID- ORCID: 0000-0003-3489-1967
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Yavin, Yshai
AU  - Yavin Y
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Balis, Dainius
AU  - Balis D
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Sun, Don
AU  - Sun D
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Xie, John
AU  - Xie J
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Canovatchel, William
AU  - Canovatchel W
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Rosenthal, Norm
AU  - Rosenthal N
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20170316
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 6KY687524K (glimepiride)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds/adverse effects
MH  - Canagliflozin/*adverse effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glomerular Filtration Rate/drug effects
MH  - Glucosides/adverse effects
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - Incidence
MH  - Kidney/drug effects
MH  - Kidney Diseases/*chemically induced/epidemiology
MH  - Male
MH  - Product Surveillance, Postmarketing
MH  - Randomized Controlled Trials as Topic
MH  - Sodium-Glucose Transporter 2 Inhibitors
MH  - Sulfonylurea Compounds/adverse effects
MH  - Time Factors
PMC - PMC5485046
OTO - NOTNLM
OT  - SGLT2 inhibitor
OT  - type 2 diabetes
EDAT- 2017/01/14 06:00
MHDA- 2018/04/04 06:00
PMCR- 2017/06/27
CRDT- 2017/01/14 06:00
PHST- 2016/11/16 00:00 [received]
PHST- 2017/01/06 00:00 [revised]
PHST- 2017/01/09 00:00 [accepted]
PHST- 2017/01/14 06:00 [pubmed]
PHST- 2018/04/04 06:00 [medline]
PHST- 2017/01/14 06:00 [entrez]
PHST- 2017/06/27 00:00 [pmc-release]
AID - DOM12876 [pii]
AID - 10.1111/dom.12876 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2017 Jun;19(6):897-900. doi: 10.1111/dom.12876. Epub 2017 
      Mar 16.